3 Stocks Moving The Health Services Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 24 points (-0.2%) at 15,303 as of Thursday, Sept. 12, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 960 issues advancing vs. 1,922 declining with 143 unchanged.

The Health Services industry currently sits down 0.3% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Intuitive Surgical ( ISRG), down 1.4%, DENTSPLY International ( XRAY), down 1.2%, Varian Medical Systems ( VAR), down 1.1%, Cooper Companies ( COO), down 1.1% and C.R. Bard ( BCR), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Mednax ( MD) is one of the companies pushing the Health Services industry higher today. As of noon trading, Mednax is up $0.74 (0.7%) to $101.60 on average volume. Thus far, 93,707 shares of Mednax exchanged hands as compared to its average daily volume of 193,700 shares. The stock has ranged in price between $100.73-$102.21 after having opened the day at $101.00 as compared to the previous trading day's close of $100.86.

MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric subspecialties, and anesthesia care physician services in the United States and Puerto Rico. Mednax has a market cap of $5.0 billion and is part of the health care sector. Shares are up 25.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Mednax a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Mednax Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Why the Boardroom Doesn't Need Ivy League Degrees

Mednax: Solid Growth at a Good Price

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

How to Invest in Your Favorite MD